- Poster presentation
- Open Access
B-type natriuretic peptide testing reduces time to discharge in patients presenting with acute dyspnea (the BASEL study)
© BioMed Central Ltd. 2004
- Published: 15 March 2004
- Congestive Heart Failure
- Clinical Group
- Prospective Randomized Control Trial
- Inhospital Mortality
- Total Treatment Cost
In patients with pulmonary disease it is often challenging to distinguish exacerbated pulmonary disease from congestive heart failure (CHF). B-type natriuretic peptide (BNP) levels are significantly higher in CHF as compared with exacerbated pulmonary disease.
This study evaluated the predefined subgroup of 226 patients with a history of pulmonary disease included in a prospective randomized controlled trial of BNP testing for the emergency diagnosis of acute dyspnea. Patients were randomly assigned to a diagnostic strategy with (n = 119, BNP group) or without (n = 107, clinical group) the use of BNP levels provided by a rapid bedside assay. The time to discharge and the total cost of treatment were recorded as the primary endpoints.
Used in conjunction with other clinical information, rapid measurement of BNP reduced the time to discharge and total treatment cost of patients with a history of pulmonary disease presenting with acute dyspnea.